Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed consent form~* Male and female between 18 - 50 years old~* AOH stage 1 or 2 according to Ficat~* Pain VAS scale \>40 mm (0-100)~Exclusion Criteria:~* Specific aetiology of AOH already known~* Cardiac and lung uncontrolled diseases~* Active malignancy untreated~* Hyper sensibility or allergy already known to ibandronate~* Pregnancy or breast feeding~* Severe kidney insufficiency (cl\<30 ml/min)~* Contra-Indications to an MRI (Pacemaker, cochlear implant...)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Ibandronate (Type: EXPERIMENTAL): Unique perfusion of ibandronate 3 mg IV
- Placebo (Type: PLACEBO_COMPARATOR): Unique perfusion of NaCl 3mg IV

Based on this trial design, predict the completion outcome and termination type (if applicable).